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Original Article
Plasma Phospholipid Transfer Protein Activity Is
Decreased in Type 2 Diabetes During Treatment With
Atorvastatin
A Role for Apolipoprotein E?
Geesje M. Dallinga-Thie,1 Arie van Tol,2,3 Hiroaki Hattori,4 Patrick C.N. Rensen,5 and
Eric J.G. Sijbrands,1 for the Diabetes Atorvastatin Lipid Intervention (DALI)
Study Group*
Plasma phospholipid transfer protein (PLTP) plays an
important role in lipoprotein metabolism. PLTP activity is
elevated in patients with diabetes, a condition with
strongly elevated risk for coronary heart disease. The aim
of this study was to test the hypothesis that statins reduce
PLTP activity and to examine the potential role of apoli-
poprotein E (apoE). PLTP activity and apoE were mea-
sured in patients with type 2 diabetes from the DALI
(Diabetes Atorvastatin Lipid Intervention) Study, a 30-
week randomized double-blind placebo-controlled trial
with atorvastatin (10 and 80 mg daily). At baseline, PLTP
activity was positively correlated with waist circumfer-
ence, HbA1c, glucose, and apoE (all P < 0.05). Atorvastatin
treatment resulted in decreased PLTP activity (10 mg
atorvastatin: 8.3%, P < 0.05; 80 mg atorvastatin: 12.1%,
P < 0.002). Plasma apoE decreased by 28 and 36%, respec-
tively (P < 0.001). The decrease in apoE was strongly
related to the decrease in PLTP activity (r  0.565, P <
0.001). The change in apoE remained the sole determinant
of the change in PLTP activity in a multivariate model. The
activity of PLTP in type 2 diabetes is decreased by atorva-
statin. The association between the decrease in PLTP
activity and apoE during statin treatment supports the
hypothesis that apoE may prevent PLTP inactivation.
Diabetes 55:1491–1496, 2006
Patients with type 2 diabetes have a severelyincreased risk for cardiovascular morbidity andmortality (1,2). An atherogenic lipoprotein pro-file, characterized by increased plasma levels of
triglycerides, decreased levels of HDL cholesterol, and
presence of small dense LDL particles, is a major determi-
nant, although the exact underlying molecular mecha-
nisms remain to be established (3). HDL plays a central
role in lipoprotein metabolism. The process of reverse
cholesterol transport, i.e., the transport of cholesterol
from peripheral tissues to the liver for degradation and
excretion, is mediated through HDL (4). Furthermore,
HDL functions as an antioxidant and anti-inflammatory
agent. All functions of HDL have a similar tenacity: they
protect against the development of atherosclerosis. Thus,
decreased levels of plasma HDL cholesterol as seen in type
2 diabetes are pro-atherogenic.
Plasma lipid transfer proteins have an important role in
remodeling of HDL. Two major lipid transfer proteins are
described: cholesterylester transfer protein and phospho-
lipid transfer protein (PLTP) (5). Plasma PLTP resides on
HDL particles and is involved in phospholipid transfer
activity (6). In vitro, its activity results in HDL conversion,
generating large HDL2 and small pre- HDL particles that
participate in cellular cholesterol efflux (7,8). This action
implies a potential antiatherogenic function of PLTP (9).
In vivo studies in PLTP-deficient mice have illustrated the
physiological importance of PLTP in transfer of surface
fragments to HDL that originate from triglyceride-rich
lipoproteins during lipolysis by the enzyme lipoprotein
lipase (10–12). Furthermore, PLTP was shown to be
involved in the hepatic secretion of apolipoprotein B
(apoB)-containing lipoproteins (13,14). This may explain
the decreased susceptibility for diet-induced atherosclero-
sis in PLTP-deficient mice (14). Studies with transgenic
mice revealed increased atherogenesis (15–17). Thus,
PLTP appears to be pro-atherogenic in vivo in mice. In line
with these animal studies, a study in humans provided
evidence for a positive association between PLTP activity
and coronary artery disease (18).
Plasma PLTP activity levels are elevated in type 2
diabetes (19), type 1 diabetes (20), hypertriglyceridemia
(21), obesity (22,23), and patients with systemic inflamma-
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tion (24). Recently, PLTP has also been implicated to play
a role in lipid metabolism in the brain (25–28). Not all
PLTP molecules in plasma are active because PLTP mass
is present in two distinct forms, one active in phospholipid
transfer and one inactive (29,30). These forms react differ-
ently to PLTP antibodies used in PLTP enzyme-linked
immunosorbent assay, and they may explain the poor
correlation between PLTP mass and PLTP activity (31).
Data in the literature suggest a potential relationship
between apoE and PLTP activity. The active form of PLTP
copurifies with apoE (32). In addition, secretion of active
PLTP and apoE from HepG2 cells are associated (33).
Interestingly, in a recent in vitro study, it was shown that
apoE is able to activate the low-activity form of PLTP,
suggesting a role for apoE in the regulation of PLTP
activity (34).
The effect of statins on PLTP has not been studied. We
hypothesized that statins influence PLTP activity by a
mechanism involving changes in the level of circulating
mass of apoE. Therefore, we investigated the influence of
atorvastatin on PLTP activity and mass and the relation
with plasma apoE in patients with type 2 diabetes of the
Diabetes Atorvastatin Lipid Intervention (DALI) study.
The DALI study was a double-blind randomized placebo-
controlled trial comparing effects of atorvastatin 10 and 80
mg daily on plasma lipids and apos (35).
RESEARCH DESIGN AND METHODS
This study comprised 215 patients enrolled in the DALI study. DALI was a
double-blind randomized placebo-controlled multicenter study evaluating the
effect of 10 vs. 80 mg atorvastatin daily on lipid metabolism, endothelial
function, coagulation, and inflammatory factors in unrelated men and women
with type 2 diabetes. The protocol and eligibility criteria have been described
in detail elsewhere (35). Briefly, men and women aged 45–75 years with
duration of diabetes for at least 1 year and an HbA1c (A1C)10% were eligible.
The diagnosis of type 2 diabetes was defined according to the American
Diabetes Association classification (36). Lipid inclusion criteria were total
cholesterol between 4.0 and 8.0 mmol/l and fasting triglycerides between 1.5
and 6.0 mmol/l. Patients were recruited in Leiden, Rotterdam, and Utrecht, the
Netherlands. The ethical committees of the participating centers approved the
study protocol, and written informed consent was obtained from all subjects.
Laboratory measurements. After an overnight fast for a minimum of 12 h,
blood was drawn into EDTA-containing tubes for analysis of lipid profiles at
baseline and after treatment for 30 weeks. Plasma was prepared by immediate
centrifugation (3,000g, 15 min, 4°C), and samples were stored at 80°C for
further analyses. Cholesterol and triglycerides were determined by enzymatic
colorimetric methods on a Hitachi 911 automatic analyzer (Boehringer
Mannheim, Mannheim, Germany). ApoB and apoAI were assayed, using
automated immunoturbidimetric assays (Tina-Quant; Roche Diagnostics,
Mannheim, Germany). Plasma apoE was analyzed automatically with a
nephelometric assay (Wako, Osaka, Japan). Plasma HDL cholesterol was
TABLE 1






n 71 72 72
Age (years) 59 8 60  8 60  8
BMI (kg/m2) 32.2 6.1 30.0  3.8 30.4  4.5
Waist (cm) 108 16 106  12 106  14
A1C (%) 8.76 1.25 8.67  1.27 8.86  1.22
Glucose (mmol/l) 10.6 3.6 10.5  3.1 10.6  2.9
Cholesterol (mmol/l) 6.03 0.88 5.94  0.95 6.04  0.90
Triglycerides (mmol/l) 2.76 0.95 2.68  0.91 2.99  1.14
HDL cholesterol (mmol/l) 1.05 0.21 1.05  0.26 1.03  0.24
ApoAI (g/l) 1.41 0.19 1.39  0.20 1.39  0.21
ApoB (g/l) 1.24 0.20 1.19  0.20 1.23  0.22
Data are the means  SD.
TABLE 2
Plasma PLTP mass and activity and apoE and apoAI levels before and after treatment
Variable Baseline Week 30 % change
PLTP mass (mg/l)
Placebo 8.88 2.57 8.83 2.70 0.6
10 mg atorvastatin 9.00 3.28 9.26 3.15 2.8*
80 mg atorvastatin 8.63 3.11 9.63 3.09 11.6†
PLTP activity (%)
Placebo 106.7 18.0 107.3 18.8 0.9
10 mg atorvastatin 107.8 18.3 99.7 16.1 8.3‡
80 mg atorvastatin 108.8 21.8 96.8 18.6 12.1†
ApoE (mg/100 ml)
Placebo 4.46 0.80 4.52 1.12 0.9
10 mg atorvastatin 4.34 1.02 3.15 0.83 28†
80 mg atorvastatin 4.68 1.17 2.99 1.06 36†
ApoAI (mg/100 ml)
Placebo 141 19 137 18 2.8
10 mg atorvastatin 139 20 138 20 0.71
80 mg atorvastatin 139 21 134 20 3.6
Data are the means  SD, and PLTP activity is % of reference plasma. Placebo: n  71; A10: n  72; A80: n  72. Test was for difference
among the three groups, adjusted for baseline value. *P  0.003 A10 vs. A80; †P  0.001 vs. placebo; ‡P  0.01 vs. placebo.
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measured by a direct enzymatic method based on polyethylene glycol–
modified enzymes, using a Hitachi 911 autoanalyzer (Roche Diagnostics). LDL
cholesterol was estimated with the Friedewald formula (37). Fasting plasma
glucose was determined on a Hitachi 917 analyzer using an UV-hexokinase
method (catalog no. 18766899; Boehringer Mannheim). A1C was determined
by high-pressure liquid chromatography, using the Variant method (catalog
no. 270-0003; BioRad).
PLTP mass and activity. Plasma PLTP mass was analyzed as previously
described (29). The between-assay coefficient of variation (CV) and within-
assay CV were 3.5 and 2.8%, respectively. Plasma PLTP activity was
measured in a liposome vesicles–HDL system as described previously (38,39).
In short, plasma samples were incubated for 45 min, 37°C, with [14C]dipalmi-
toyl-phosphatidylcholine–labeled liposomes and an excess of HDL, followed
by precipitation of the liposomes with a mixture of NaCl, MgCl2, and heparin
(final concentrations 230 mmol/l, 92 mmol/l, and 200 units/ml, respectively).
The measured PLTP activities are linearly related to the amount of plasma
used in the incubations (0.5–1.0 l). The method is not influenced by the
phospholipid transfer–promoting capacities of cholesterylester transfer pro-
tein (38). Plasma PLTP activity was related to the activity measured in a
reference plasma pool, based on plasma collected from 200 randomly selected
healthy individuals, and is expressed as the percentage of the activity
measured in this reference plasma, which was included in every assay. The
PLTP activity in this reference plasma was 21.2 mol  ml1  h1. The
between- and within-assay CVs were 4.8 and 3.5%, respectively.
Statistical analysis. All data are expressed as the means SD. All statistical
analyses were carried out with SPSS software (version 12.0). Mean differences
between the groups were analyzed, using ANOVA. To analyze determinants of
PLTP activity and PLTP mass, we used the following strategy. First, univariate
linear regression analyses was performed in the total cohort with PLTP
activity and PLTP mass as dependent variables and the determinant of interest
as an independent variable. Second, multivariate regression analysis was
performed with PLTP activity and PLTP mass as dependent outcome vari-
ables, sex and waist as confounders, and statistically significant variables as
independent variables. Third, the effect of treatment on PLTP activity, PLTP
mass, and apoE was analyzed with two-way ANCOVA, using a placebo-
controlled setting. Throughout, a two-tailed P value of 0.05 was interpreted
as indicating a statistically significant difference.
RESULTS
The characteristics of the 215 patients have been exten-
sively described (35) and are summarized in Table 1. The
atherogenic lipoprotein profile of the patients was charac-
terized by elevated plasma triglycerides (2.81  1.01
mmol/l) and decreased plasma HDL cholesterol (1.04 
0.24 mmol/l) levels. The mean plasma cholesterol levels
were 6.0  0.9 mmol/l. Average A1C was 8.3  1.1%, and
plasma glucose was 10.6  3.2 mmol/l. The average
duration of diabetes was 10.5 years.
Baseline findings. Baseline plasma PLTP mass concen-
trations varied from 2.50 to 24.50 mg/l, with an average of
8.84  3.01 mg/l, and were similar in the three treatment
groups (Table 2). Plasma PLTP activity at baseline varied
from 64.4 to 187.1%, with an average of 107.6  19.4%, and
was identical in the three treatment groups. The correla-
tion between baseline plasma PLTP mass and activity was
low (r  0.120, NS). Baseline plasma apoE concentrations
were 4.49  1.02 mg per 100 ml. One important determi-
nant for plasma apoE levels is the apoE genotype. In the
present study cohort, the apoE genotypes were in Hardy-
Weinberg equilibrium (2 2.916, degrees of freedom 3,
P  0.4): 62% of the patients had the apoE3/E3 genotype,
17% apoE2/E3, 3% apoE2/E4, 17% apoE3/apoE4, and 1%
apoE4/E4. The average apoE and PLTP activity levels per
apoE genotype group are shown in Table 3. No significant
effect of apoE genotype on PLTP activity was found.
Waist circumference, plasma glucose, A1C, and plasma
apoE were associated with baseline PLTP activity (Table
4, Fig. 1). In multivariate analyses, adjusted for age and
FIG. 1. Relationship between plasma PLTP activity
and plasma apoE levels at baseline. Spearman corre-
lation coefficient rs  0.21, P < 0.05.
TABLE 3







ApoE 2/3 34 5.24 1.14 108.8 17.8
ApoE 3/3 133 4.31 0.85 108.0 21.2
ApoE 2/4 6 5.18 0.80 104.4 11.1
ApoE 3/4 37 4.17 0.92 106.2 16.5
ApoE 4/4 4 4.53 0.92 99.3 12.2
Data are the means  SD. Plasma PLTP activity is percent of
reference plasma.
TABLE 4
Correlation between plasma PLTP activity and baseline parame-
ters







*All analyses were performed using multiple linear regression anal-
yses, adjusted for age and sex and each determinant separately. HDL
cholesterol, apoAI, and triglycerides do not contribute significantly
to the variation in PLTP activity.
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sex, only waist circumference and plasma apoE remained
major determinants of plasma PLTP activity. None of the
other lipid (including cholesterol, LDL cholesterol, HDL
cholesterol, and triglycerides) and apo (apoAI and apoB)
parameters showed a significant correlation. Plasma PLTP
mass is known to be predominantly determined by the
levels of plasma HDL cholesterol and apoAI (21). In our
analyses both HDL cholesterol and apoAI contributed to
the variation of plasma PLTP mass, independent of age,
sex, and waist circumference. Plasma apoE and triglycer-
ide concentrations were less important determinants (Ta-
ble 5).
Treatment with atorvastatin. As expected, adjusted for
the placebo effect, treatment with atorvastatin resulted in
a dose-dependent decrease in plasma total cholesterol,
LDL cholesterol, and apoB (all P  0.001) (35). Plasma
HDL cholesterol increased by 6.0 and 5.2% with 10 and 80
mg atorvastatin, respectively (P  0.05), whereas plasma
apoAI levels remained unchanged (Table 2). Plasma PLTP
activity decreased by 8.3% (P  0.01) and 12.1% (P 
0.001), respectively. The difference between the two
groups did not reach statistical significance, but the trend
was significant (P  0.01). In contrast, plasma PLTP mass
increased by 2.8% (NS) and 11.6% (P  0.001), respec-
tively. The difference between 10 and 80 mg atorvastatin
was significant (P  0.005). Plasma apoE levels were
strongly decreased after atorvastatin treatment by 28 and
36%, respectively (both P  0.001 vs. control). In a
multivariate placebo-controlled analyses, including all
lipid and apo parameters, the decrease in PLTP activity
was only predicted by the decrease in apoE (standardized
coefficient   0.529, P  0.0001) (Fig. 2). Similar results
were obtained when only individuals with the apoE3/E3
genotype were analyzed (n  133, r  0.513, P  0.001),
illustrating that the effect is independent of the apoE
genotype.
DISCUSSION
In patients with type 2 diabetes, we found that atorvastatin
treatment resulted in a decrease in PLTP activity and an
increase in PLTP mass, leading to a substantial change in
mass-adjusted activity. Statistical analysis revealed that
the change in apoE and the change in PLTP activity are
associated, thereby supporting the concept that apoE may
be essential for the stability of the PLTP protein and its
activity.
It has been shown that patients with type 2 diabetes
have increased levels of plasma PLTP activity (19,40).
Positive associations have been reported for PLTP activity
and parameters of body composition, such as body fat,
BMI, and waist circumference (22,23,41). Also in the
present study, both waist circumference and BMI were
positively correlated with PLTP activity. In multivariate
analysis, however, waist circumference was the better
predictor. Increase in abdominal fat accumulation, as
represented by increase in waist circumference, strongly
relates to insulin resistance (42). Therefore, it is not
surprising that patients with hypertriglyceridemia without
diabetes have increased levels of PLTP activity as well
(21). However, neither plasma glucose levels nor A1C
were strong predictors for PLTP activity in the present
study, even though glycemic control was suboptimal. Also,
no sex-specific difference in PLTP activity or mass was
found.
Mice with a genetic deficiency of PLTP have impaired
hepatic secretion of apoB-containing particles, which is in
favor of a role for PLTP in the biosynthetic pathway of
VLDL by enabling donation of lipids to the nascent parti-
cles (14). In accordance with this mechanism, overexpres-
sion of human PLTP in transgenic mice results in elevated
rates of hepatic VLDL secretion (43). Indeed, a number of
clinical studies have reported the existence of a link
between plasma apoB or LDL cholesterol and PLTP activ-
ity (20,41), but in the present study, we were unable to find
evidence for this association. It has to be noted that we
selected our patients on the presence of raised plasma
triglycerides. As a result, we observed relatively small
ranges in plasma apoB and cholesterol levels (Table 1),
which could have obscured a relationship between PLTP
activity and LDL cholesterol levels. Positive correlations
with plasma triglycerides and cholesterol have been re-
ported in a Finnish population study (44), but this could
not be replicated in the present study, where correlations
with triglycerides (r  0.10, NS) and cholesterol (r  0.00,
NS) were only weak or absent.
Plasma apoE levels at baseline were associated with
PLTP activity in both univariate and multivariate analyses.
None of the other lipid variables or determinants of
FIG. 2. Relationship between the change in apoE (y-axis) and the
change in PLTP activity (x-axis) during atorvastatin treatment.
Spearman correlation coefficient rs  0.595, P < 0.001.
TABLE 5
Correlation between plasma PLTP mass and baseline parameters








*All analyses were performed using linear regression analyses,
adjusted for age and sex and each determinant separately. A1C and
glucose do not contribute significantly to the variation of PLTP mass.
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glucose homeostasis, like glucose levels and A1C, showed
any significant contribution. PLTP mass, on the other
hand, strongly positively correlated with plasma HDL
cholesterol and apoAI and negatively with plasma triglyc-
erides in univariate analysis. Multivariate analysis revealed
that PLTP mass was predominantly explained by HDL
cholesterol levels. Plasma PLTP is present in two forms:
one form with little, if any, phospholipid transfer activity
and another form with high activity. Both are associated
with macromolecular complexes of different size (30,32).
The inactive form is present on larger HDL particles,
compared with the active form. The currently used PLTP
mass assay has been extensively validated and is capable
of analyzing both the catalytically active and inactive
forms (45). Because the greater part of plasma PLTP is
inactive and because inactive PLTP copurifies with apoAI
(32), it can be appreciated that PLTP mass and apoAI, as
well as HDL cholesterol, are related (21).
Atorvastatin treatment significantly reduced plasma
apoE levels and plasma PLTP activity, whereas total PLTP
mass was increased. Evidence for a possible role for apoE
in PLTP homeostasis has been obtained in a number of
different studies. The active form of PLTP copurifies with
apoE, whereas the inactive form is associated with apoAI
(32). In addition, active PLTP secreted from HepG2 cells
coelutes with apoE but not with apoAI (46). Furthermore,
apoE but not apoAI is able to convert inactive PLTP into
the active form (34). In light of these and our present
observations, we hypothesize that atorvastatin, via its
lowering effect on apoE concentration mediated through
elevation of hepatic LDL receptors, destabilizes the active
form of PLTP. As a consequence, PLTP could be partly
inactivated, resulting in lowering of PLTP activity. Finally,
more inactive PLTP may have contributed to the observed
elevation of plasma PLTP mass. In conclusion, the present
study shows, for the first time, that a statin is able to
decrease PLTP activity and supports our hypothesis that
apoE may stabilize PLTP in vivo.
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